RxDoctor Payments Data

Harpreet Bhalla, MD

Interventional Cardiology · Gastonia, NCNPI 1255327045

Payments from drug & device makers

$6,166in general payments, 2019–2025

Across 107 payments — averaging $57.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Medtronic$565
  • Boston Scientific$535
  • Pfizer$174
  • Shockwave Medical, Inc$164
  • E.r. Squibb & Sons, L.L.C.$154
  • plus $842 from 16 others

What the payments were for

  • Travel & lodging$1,76129%
  • Food & beverage$4,40571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,166 in reported general payments places this provider in the 40th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$41,030
Medicare patients
163
Services billed
413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban86$58,763
JardianceEmpagliflozin40$34,140
XareltoRivaroxaban30$24,727
EntrestoSacubitril/Valsartan32$22,809
Metoprolol Succinate161$2,139
Nitroglycerin PatchNitroglycerin11$762
Atorvastatin Calcium78$616
Spironolactone78$562
Chlorthalidone32$436
Ezetimibe40$387
ClopidogrelClopidogrel Bisulfate35$375
Valsartan12$333
Rosuvastatin Calcium29$315
Amlodipine Besylate48$261
Carvedilol43$255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$174$58,76386 claims
Boehringer IngelheimJardiance$54$34,14040 claims
Johnson & JohnsonXarelto$100$24,72730 claims
NovartisEntresto$21$22,80932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 180 interventional cardiology providers in North Carolina.

Other interventional cardiology in Gastonia

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →